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ABSTRACT 
With increased automation and larger compound collections, the development of high-
throughput screening (HTS) started replacing previous approaches in drug discovery from 
around the 1980s onwards. However, even today it is not always appropriate, or even feasible, to 
screen large collections of compounds in a particular assay. Here, we present an efficient method 
for iterative screening of small subsets of compound libraries. With this method the retrieval of 
active compounds is optimized using their structural information and biological activity 
fingerprints. We validated this approach retrospectively on 34 Novartis in-house HTS assays 
covering a wide range of assay biology, including cell proliferation, antibacterial activity, gene 
expression and phosphorylation. This method was employed to retrieve subsets of compounds 
for screening, where selected hits from any given round of screening were used as starting points 
to select chemically and biologically similar compounds for the next iteration. By only screening 
~1% of the full screening collection (~15,000 compounds), the method consistently retrieves 
diverse compounds belonging to the top 0.5% most active compounds for the HTS campaign. 
For most of the assays over half of the compounds selected by the method were found to be 
among the 5% most active compounds of the corresponding full-deck HTS. In addition, the 
stringency of the iterative method can be modified depending on the number of compounds one 
can afford to screen, making it a flexible tool to discover active compounds efficiently. 
Keywords: HTS screening; Iterative screening; in silico heuristic compound selection 
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INTRODUCTION 
Early drug discovery traditionally has been the result of a close collaboration between chemists, 
pharmacologists and clinical scientists, where knowledge from pharmacology and (medicinal) 
chemistry was combined to design potentially active molecules for testing.
1,2
 From around the 
1980s onwards rapid improvements in automation and combinatorial chemistry led to the 
development and increasing acceptance of high-throughput screening (HTS), which allows rapid 
screening of large collections of compounds using robotics and automated data processing. This 
allowed enabled HTS to be used to study relationships between compounds and putative 
biological targets on a very large scale, so that libraries of 1-2 million compounds are routinely 
screened in big pharmaceutical companies, several times per year.
2,3
 Conceptually, HTS aims to 
screen large numbers of molecules in a brute-force approach to identify hits, and the most 
promising chemical entities are then selected as starting points for further investigation. It is 
hoped thatThe rationale behind screening large numbers of molecules is that it increases the 
chances of finding promising chemical entities. However, the previous often iterative cycles of 
design–screen–refine in small interdisciplinary project teams were somewhat lost. 
Over the last few decades, HTS has hence become increasingly popular and has increased 
augmented in capacity from being able to screen tens of thousands of compounds a day to over 
100,000 compounds a day, and has become – besides many other techniques – of crucial 
importance for early drug discovery.
4–6
 However, HTS also has some significant drawbacks. 
Cell-free HTS campaigns, such as biochemical target-based assays, are not adequately predictive 
of compounds’ ADMET (absorption, distribution, metabolism, excretion and toxicity) properties 
which are important pharmacokinetic parameters for drug development.
7
 For cell-based 
phenotypic HTS assays, which can be more predictive of certain ADMET properties such as 
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bioavailability and cytotoxicity, target deconvolution is an important challenge.
8
 Additionally, 
HTS campaigns sometimes cannot be performed at scale for complex biological systems that 
cannot be mass-produced (e.g. organoids).
9
 Finally, and of most relevance for the current study, 
HTS remains a resource-intensive endeavor with a large fraction of the compounds screened 
being inactive or uninteresting. The latter renders the identification of smaller screening sets 
which lead to a significant fraction of active chemical matter detected very relevant.
4
  
The mentioned drawbacks prompted efforts to optimize various aspects of HTS campaigns, such 
as compound library design (for example, based on chemical diversity, where libraries are 
chosen on the basis of chemical knowledge),
10–14
 post-HTS data analysis for triaging active 
compounds (in order to select subsets for further validation)
15,16
 and selecting novel compounds 
similar to active compounds detected in the assay for further investigation.
17–21
 Given the recent 
perceived ineffectiveness of target-based HTS,
22
 a shift to phenotypic HTS has occurred,
8
 hence 
increasing the need for target identification methods. In this regard, a high-throughput screening 
fingerprint (HTS-FP) capturing past performance of compounds across a number of screens was 
developed by Petrone et al. at Novartis,
23
 which allows the comparison of compounds according 
to their bioactivity across a range of HTS assays. This approach was used for both similarity 
searching and various machine learning methods for target identification of hits from phenotypic 
screens. Later, a public version of the same fingerprint was developed and analyzed by Dančík et 
al.,
24
 who also reported its usefulness in the elucidation of compound mode of action. However, 
despite these computational advances in post-screen analysis, HTS campaigns remain an 
expensive endeavor.  
In this study, we aim to address efficient ways of screening subsets of compound libraries, 
instead of screening entire compound libraries, while at the same time optimizing the retrieval of 
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active compounds. We developed and retrospectively validated an iterative screening method on 
Novartis in-house HTS data, in which selected hits from any given round of screening were used 
as starting points to select chemically and biologically similar compounds for the next iteration. 
This approach was developed with the explicit aim to select much smaller subsets of compounds 
with enriched activity, by harnessing the bioactivity information of compounds in the previous 
iteration. While briefly mentioned by Mayr et al. as an idea,
5
 and used on a small scale by 
Keenan et al. for the design of plasmodial kinase inhibitors,
25
 the concept of iterative screening 
has not been explored systematically in the published literature. A related concept has been 
previously described by Schneider et al. in the context of iterative virtual synthesis and testing of 
individual molecules, where molecules are designed automatically using evolutionary algorithms 
and particle swarm optimization.
26
 However, our approach differs considerably, because we 
iteratively generate sets of molecules instead of individual molecules, hence investigating the 
concept on a much larger scale. 
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METHODS 
HTS data 
Novartis proprietary HTS assays comprising at least 1,300,000 compounds with an inhibitory 
assay readout were used, resulting in a total of 34 assays, of which 11 were cell-based assays and 
23 were cell-free (biochemical) assays. These assays covered a wide number of biological 
events, including cell proliferation, antibacterial activity, gene expression and phosphorylation 
(Supplementary Table S1). 
Starting set for initial screening round 
We used a starting set of well-studied and manually curated compounds, many with tested 
clinical relevance, known to cover a large amount of druggable bioactivity space and of which 
the mechanism of action (MoA) is known. This set (the MoABox) comprised 2,757 compounds 
and is used as a starting point for many phenotypic screening projects at Novartis due to the 
high-quality annotations of each compound. The physicochemical properties and the chemical 
and biological diversity of the MoABox were calculated using RDKit
27
 (Supplementary Figures 
S1 and S2). The design of the MoABox inherently entails that most compounds have properties 
favorable for cell-based screening. Owing to operational turnover of the compound archive, not 
every full-deck HTS contains every compound of the MoABox. Therefore, the starting set for 
each specific assay was the MoABox compounds present in it at the time it was performed. The 
smallest starting set comprised 2,050 compounds, whereas the largest comprised 2,692 
compounds.  
In order to determine the importance of the starting set for good performance, we repeated our 
analysis with 10 randomly chosen starting sets and the results were compared to those obtained 
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with the MoABox as starting set. These sets were obtained by repeatedly selecting a random 
subset from the entire screening deck of equal size to that of the MoABox present in the 
corresponding assay, minus any MoABox compounds that might have been coincidentally 
selected. 
Iterative screening algorithm (ISA) 
For any given set of compounds we are able to look up its activities in a past assay with ~1.3M 
compounds. This in silico screening allows not only a relative ranking (according to activities 
within the subset) but also an absolute ranking (according to the 1.3M compounds). Our aim was 
to iteratively optimize the absolute ranking of subsets of compounds, thereby efficiently 
selecting highly active compounds and steering the screening process towards success with much 
smaller compound sets. Therefore, the method developed in this study consists of three iterative 
procedures (see Figure 1): (1) ranking of compounds based on retrospective activity data, (2) 
selection/triaging of hits (3) expanding from hits to close analogs based on chemical and 
biological similarity metrics. Since this study is a retrospective analysis on HTS data, the ranks 
of the compounds selected correspond to the ranks of the same compounds had they been 
screened in a full-deck screen. Our method is fundamentally different from a basic similarity 
search using active probes, because we perform a similarity search iteratively based on active 
compound information at every round of screening, rather than only once. Circular fingerprints
28
 
(SciTegic ECFP4-like) were used as features for determining chemical similarity and HTS-
fingerprints (HTS-FP)
23
 were used as features for determining biological similarity. 
Metrics used for performance assessment  
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We used two criteria for evaluating compound sets at each iteration: (1) the rank distribution 
based on compound activity and (2) the cumulative coverage of Murcko scaffolds
29
 found in the 
top 0.5% of compounds ranked by activity. In conjunction, these criteria assess the retrieval of 
not only active, but also structurally diverse sets of compounds. In the below, a median rank 
cutoff of 65,000 is sometimes used to assess performance; this corresponds to 5% of a total 
screening collection of 1.3 million compounds. 
Systematic exploration of parameters 
The number of compounds triaged per iteration as well as the number and types of expansions 
affect the size and diversity of the compound sets selected. First, the number of top-performing 
compounds triaged can be varied. Second, expansions can be adjusted (chemical and/or 
biological similarity), as well as the corresponding Tanimoto
30
 similarity cut-off and maximum 
number of expansions per compound. Moreover, the maximum number of compounds 
originating from the same parent compound can be adjusted in order to limit the number of 
closely related analogs. We systematically explored the influence of these parameters in a 
number of in silico experiments (see Table 1), where the influence of each parameter was 
analyzed individually. Experiment 1 was considered as a realistic reference experiment that 
balances performance and the number of compounds screened over 10 iterations (~1% of entire 
collection,  ~15,000 compounds). All other experiments varied one parameter, therefore allowing 
an assessment of its influence with respect to the reference experiment. For example, a 
comparison of experiment 3 with experiment 1 shows the effect of doubling the number of 
compounds triaged per iteration from 100 to 200. 
Data analysis 
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The workflow comprised Python and Perl scripts for data analysis, the Indigo toolkit
31
 and 
RDKit
27
 for cheminformatics calculations. Spotfire
32
 was used for data exploration and R
33
 and 
Cytoscape
34
 were used for the visualization of results.  
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RESULTS AND DISCUSSION 
Here we present in detail the results belonging to the reference experiment, followed by a 
comparison to other experiments. Experiments 4, 6 and 7 showed the same results as the 
reference experiment and are therefore not discussed separately; these experiments highlight, 
however, that more than 50 expansions or a more stringent HTS-FP similarity cut-off do not 
change the results. 
Iterative screening is highly effective across assay types 
The median rank of the compounds selected was 36,101 (excluding the starting set) across all 
assay types, which corresponds to the top ~2.8% of a collection of ~1.3M compounds. In other 
words, half the compounds selected across all iterations (except for the starting set) are found 
among the top 2.8% of the corresponding 1.3M compound screen, indicating a clear enrichment 
in activity of the compounds selected. Of note, the performance is consistent for a large number 
of different assay types (median rank below 65,000, see Figure 2). However, for the types 
enzyme activity/cleavage assay, protein cleavage assay, protein functional assay and protein-
protein binding assay the performance was reduced, as evidenced by a median rank greater than 
65,000 combined with a higher standard deviation. 
Interestingly, performance is better for the cell-free assays than the cell-based assays (rank 
distributions for both assay formats is shown in Figure 3). In order to investigate whether this 
difference was statistically significant, a paired t–test was performed for the median ranks across 
iterations 1 to 10. In addition, a Kolmogorov–Smirnov test was performed for every iteration on 
compound ranks of different assay formats. All p-values were smaller than 10
-5
, hence indicating 
a statistically significant difference in distribution of rank between cell-free and cell-based 
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assays. This difference is likely due to the fact that in order for compounds to have an effect in 
cell-based assays, they have to be able to cross the cell membrane to reach the target of interest 
(in cases when this target is not membrane-bound). Hence, these compounds must have suitable 
physicochemical properties (such as permeability), in order to be effective. Since our method on 
purpose did not distinguish between cell-free and cell-based assays, these results are in line with 
expectations; however, specific compound criteria for cell-based assays (e.g. incorporation of 
logP values, past performance in cell-based assays) are likely to diminish this observed gap in 
performance between the two assay formats in the future. As mentioned before, the MoAbox 
content is geared towards hypothesis-generating cell-based phenotypic screening; as a result, this 
set of compounds performs equally well on cell-based and cell-free assays (Figure 3, iteration 0). 
Next, median compound ranks were evaluated per assay type (Figure 4). The iterative method 
performs consistently well for the majority of assay types (median ranks are smaller than 
100,000 for iterations 1–10 for 11 out of the 16 assay types), but there are a number of outlier 
assay types for which the median rank of compounds selected swiftly deteriorates after around 
iteration 3. These assays cover the biological events protein-protein binding, protein cleavage, 
protein function and enzyme activity/cleavage, and are the same ones shown to have an overall 
median rank above 65,000 (Figure 2). These results suggest that expansions in chemical and 
biological space are unable to effectively retrieve the most active compounds for these assay 
types after the first few iterations.  
Chemical diversity analysis of iterative screening results 
In addition to the rank distribution of the iteratively selected compounds, we also analyzed the 
percentage of highly active scaffolds cumulatively retrieved. Highly active scaffolds were 
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separately defined for each assay as the Murcko scaffolds
29
 belonging to the top 0.5% most 
active molecules in the assay. While Murcko scaffolds are useful for assessing structural 
diversity of cyclic compounds (the definition by Bemis and Murcko
29
 is based on ring systems 
and linkers), this measure of diversity is biased for assays where many aliphatic compounds are 
hits. In the absence of a more inclusive and/or appropriate definition of scaffold, the following 
analysis only includes chemical matter with a defined Murcko scaffold. 
The average retrieval rate of highly active scaffolds after 10 iterations across all assay types is 
41% (~1,600 unique scaffolds per assay, ~9 analogs per scaffold), with an average of 14,959 
compounds screened across all iterations per assay. Examples of commonly retrieved scaffolds 
are shown in Supplementary Figure S3, where scaffold 1 is the second most commonly retrieved 
scaffold, corresponding to a prevalence of 1.4% in the compounds screened for all assays in 
iterations 1 to 10. These results indicate that our method is able to prioritize diverse chemical 
matter despite much smaller screening sets. In addition, it performs substantially better than a 
traditional similarity search as the retrieval of highly active scaffolds is only 11% in the first 
iteration where the similarity search would stop, compared to 41% after 10 rounds of iterative 
screening. 
The percentage of cumulatively retrieved highly active scaffolds steadily increases with the 
iteration count (Figure 5), with the steepest increases occurring in the earliest iterations. Most 
assay types display a scaffold retrieval of ~30–45% after 10 iterations. The calcium 
quantification assay showed relatively poor scaffold coverage (~20% after 10 iterations), 
whereas the phosphorylation assay, typically used for kinase inhibitors, showed much better 
scaffold coverage compared to other assay types (~55% after 10 iterations). Given the presence 
of many series of high-quality kinase inhibitors from past drug discovery programs in the 
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Novartis screening archive, in combination with the promiscuity of kinase inhibitor binding,
35,36
 
it is likely that many active inhibitors retrieved are structurally/biologically similar. Hence, this 
is a possible explanation for the preferred retrieval of a higher number of active scaffolds for 
phosphorylation assays. Another interesting observation is that the assays for protein-protein 
binding, protein cleavage and enzyme activity show mediocre median ranks (>65,000), while 
having average scaffold retrieval rates (30-40% retrieval after 10 iterations). This suggests that 
while our ISA is able to retrieve many compounds present in the top 0.5% of most active 
compounds (to an extent comparable with the majority of other assays), many inactive 
compounds are retrieved as well, resulting in a higher standard deviation in rank (see Figure 2). 
The hypothetically best scaffold retrieval among the top 0.5% of compounds screened would be 
achieved by sorting the top 0.5% of compounds by activity and picking their scaffolds. The 
comparison between the hypothetically best scaffold retrieval and iterative scaffold retrieval rate 
is shown in Supplementary Figure S4. For example, after picking 5,000 compounds this best 
possible performance retrieves ~75% of highly active scaffolds, compared to ~10–25% of highly 
active scaffolds (depending on assay type) retrieved iteratively and ~0.4% that would be 
retrieved if selection was random. In other words, iterative screening of ~15,000 compounds 
recovers a third of the structural diversity of the top 5,000 compounds of a 1.3M compound 
screen. 
The fraction of highly active scaffolds retrieved was also analyzed across all assay types. Here, 
we determined the fraction of highly active scaffolds for each iteration (see Figure 6). We 
observed that, in general, the active scaffolds which are easily identified are quickly retrieved: 
for the first few iterations the fraction of highly active scaffolds retrieved sharply increases from 
~10% to ~30-80%, after which it slowly decreases, indicating the progressive difficulty in 
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finding the remaining highly active scaffolds. A possible explanation is the presence of 
unreachable singletons in the screening archive that are beyond the expansions we implemented 
thus far. 
Visualization of stepwise exploration of chemical space 
In order to illustrate the iterative compound selection in more detail, we showed the expansions 
for an inhibitory cell-free kinase assay in a network graph (see Figure 7). All compounds from 
the starting set (0
th
 iteration) leading to no further expansions have been omitted from the 
network graph, whereas those that lead to at least one further expansion are depicted on the large 
circle on the left part of the figure. Compounds are color-coded according to their rank 
(lower/better and higher/worse ranks are represented by green and red nodes, respectively) and 
edges are colored according to the expansion type (chemical similarity expansions are orange 
and biological similarity expansions are turquoise). Certain compounds from the starting set lead 
to very few further expansions, and hence produce very few branches. Other compounds lead to 
a larger number of expansions, as can be seen in the upper-right corner of the figure: all the 
compounds present in that subnetwork represent expansions from one single compound of the 
starting set. In the lower-right corner of the figure, we show an example of scaffold hopping, 
which is commonly observed for biological similarity (HTS-FP) expansions, enabling the 
method to explore chemical space that is not reachable via chemical similarity. In addition, the 
depiction of activity cliffs
37
 (represented by bold and wide edges) allows the identification of 
scaffold hopping indicative of a relatively sharp increase in activity. 
Tuning iterative screening to assay requirements 
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The number of compounds triaged per iteration has a large effect: as more compounds are 
carried forward, both the median ranks and the scaffold retrieval for compounds selected in 
iterations 1–10 increase (comparison of experiments 2 and 3 with reference, see Figure 8). When 
the number of compounds triaged was increased from 50 to 100 and from 100 to 200, median 
ranks of the compounds selected in iterations 1–10 increased significantly from 23,517 to 36,101 
in the first case, and from 36,101 to 63,721 in the second case (paired t–test p-values of 1.210-3 
and 3.410-4, respectively). Scaffold retrieval increased from 20% to 28%, and from 28% to 38% 
for the same comparisons, with respective paired t–test p-values of 1.110-5 and 9.910-6. Less 
stringent hit selection during triaging leads to more subsequent expansions and increases the total 
number of compounds screened. The overall net result is an increased retrieval of active 
scaffolds at the cost of screening more inactive compounds as evidenced by higher median ranks  
(the fraction of highly active scaffolds retrieved at each iteration decreases as more compounds 
are triaged, see Supplementary Figure S5). To illustrate the effect of varying the number of 
compounds triaged per iteration in more detail, we show possible expansions for an inhibitory 
cell-free kinase assay in a network graph (see Supplementary Figure S6). For example, the 
compound subnetwork and corresponding structure-activity relationships in the lower-right 
corner of the figure are only explored when triaging 100 or more compounds per iteration. 
When investigating the dependence of scaffold coverage on fingerprint type, we found that HTS-
FP-based and structure-based expansions accounted for 90% and 50%, respectively, of total 
highly active scaffold retrieval after 10 iterations (Supplementary Figure S7). Since HTS-FPs 
capture the biological profile of compounds, HTS-FP similarity leads to more structurally 
diverse sets of biologically similar compounds compared to structure-based expansions. 
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Increasing the Tanimoto
30
 cut-off from 0.6 to 0.8 (comparison of experiment 5 to the reference 
experiment) for structure-based expansions decreased both median compound ranks from 36,101 
to 16,831 (paired t–test p-value of 9.410-4) and scaffold retrieval from 28% to 16% (paired t–test 
p-value of 2.610-6). The maximum number of compounds triaged per parent compound did not 
have a clear effect on the diversity nor the ranks of the compounds screened. Lowering this 
number from 5 (reference experiment) to 2 (experiment 8) resulted in a 2% higher scaffold 
retrieval (paired t–test p-value of 0.047), whereas an increase to 10 (experiment 9) had no 
significant effect on either median ranks or scaffold retrieval. In summary, the number of 
compounds triaged was the most influential factor, which can be adjusted depending on the 
number of compounds one intends (or can afford) to screen. 
Finally, iterative screening was repeated with 10 randomly chosen starting sets and the results 
were compared to those obtained with the MoABox as starting set. The latter resulted in better 
median ranks only until the first iteration and virtually identical median ranks from iteration two 
onwards, and slightly higher scaffold retrieval throughout all iterations (Supplementary Figure 
S8). While minor differences across starting sets can be observed, the key findings presented in 
this study are independent of the precise composition of the starting set. However, availability of 
a high-quality starting set, as the MoAbox for us, can provide biological insight early on through 
comprehensive compound annotations. 
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CONCLUSION 
Even though alluded to in the literature and theoretically appealing, no comprehensive practical 
evaluation of iterative screening was published. In this study We we have performed an 
unequalled large-scale validation of iterative screening on 34 HTS assays comprising at least 
1,300,000 compounds and showed greatly improved efficiency over conventional HTS 
campaigns. For most assays, half of the compounds found by iterative screening of only 1% 
(~15,000 compounds) of the entire collection correspond to the top 5% of the full collection 
screen. Put differently, screening only 1% of the collection provides ~7,500 top-quality hits for 
further optimization. On average, the compounds selected covered over 40% of the scaffolds 
belonging to the top 0.5% most active compounds for each assay, hence also ensuring structural 
diversity. Our method allows for exit points during the iterative screening process: performing 
large numbers of iterations is not necessary in order to retrieve active compounds, as they are 
retrieved starting from the 1
st
 iteration already, and therefore, a large investment in resources 
upfront is not required. As expected, the method in its current state performs better for cell-free 
assays compared to cell-based assays; a future improvement can gear towards physicochemical 
properties more adapted to cell-based screens.  
We used network graphs to visualize the compound selection process, and to highlight activity 
cliffs,
37
 scaffold hopping and the effect of changing the number of compounds triaged (which 
was found to have the largest influence on compound selection). As an outlook for further 
refinement of our method, we propose (1) investigating activity cliffs
37
 (to be able to prioritize 
expansion types) and (2) employing iteratively-retrained machine-learning methods
20
 to rank the 
screening collection in parallel to the structure-based and HTS-FP-based expansions currently 
performed. We believe that the iterative method developed here can easily be fine-tuned for 
 18 
specific assay types, provides multiple exit points and can potentially lead to considerable 
savings in both time and resources.   
 19 
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Figure 1. Iterative screening algorithm (ISA) overview. The ISA developed in this study consisted of three 
iteration steps: (1) ranking of compounds based on retrospective data, (2) triaging of (i.e. selecting) top-performing 
compounds and (3) expanding from top-performing compounds to close analogs based on chemical and biological 
similarity metrics. The starting set comprises the MoABox compounds present in the HTS assay. The ISA allows for 
adjustment of parameters at the triaging stage (the number of compounds carried forward, and the number of 
compounds originating from the same parent compound to limit large numbers of closely related analogs). At the 
expansion stage, the parameters used (chemical and/or biological similarity) can be adjusted, as well as the 
corresponding similarity cut-off and maximum number of expansions per compound. 
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Figure 2. Ranks of compounds from iterations for all assay types. Boxplots of ranks for all compounds selected by the ISA for iterations 1–10 (excluding the 
starting set) are represented for each assay type. The performance for enzyme activity/cleavage assay, protein cleavage assay, protein functional assay and 
 21 
protein-protein binding assay is much worse (median rank of 200,000 on average) compared to other assays, with also a broader rank distribution. Blue: median 
rank below 65,000; red: median rank above 65,000. The first 65,000 compounds correspond to the top ~5% of 1.3M. 
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Figure 3. Ranks of iteratively selected compounds for cell-free and cell-based assays. Green: cell-free assays, orange: cell-based assays. There is a consistent 
difference in median rank (and interquartile range, extension of boxplot) across iterations 1 to 10 between cell-free and cell-based assays. This indicates the 
relative difficulty in selecting compounds that are able to satisfy cell-based screening requirements (e.g. cell permeability). Median ranks are significantly 
different (paired t–test, p-value < 10-5), as are the rank distributions for each iteration (Kolmogorov–Smirnov test, p-value < 10-5).  
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Figure 4. Median rank per iteration across assay types. The median rank of the compounds of the selected subset at each iteration is plotted versus iteration. 
The ISA performs consistently well for most assay types, but there are a number of assays for which the median rank of compounds selected swiftly deteriorates 
after around iteration 3. These assays are for protein-protein binding, protein cleavage, protein function and enzyme activity/cleavage, and are the same ones 
shown to have an overall median rank greater than 65,000 (Figure 2). 
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Figure 5. Cumulatively retrieved highly active scaffolds (%). For all assay types, the percentage of cumulatively retrieved highly active scaffolds (scaffolds of 
the 0.5% most active compounds of the full HTS) steadily increases, with the steepest increases occurring in the earliest iterations. Most assay types display a 
scaffold retrieval of between ~30–45% after 10 iterations. The calcium quantification assay showed relatively poor scaffold coverage (~20% after 10 iterations), 
whereas the phosphorylation assay showed much better scaffold coverage compared to other assay types (~55% after 10 iterations).  
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Figure 6. Fraction of highly active scaffolds retrieved (%). The ISA exhibits a general trend for all assays: for the first 2 or 3 iterations the fraction of highly 
active scaffolds retrieved per iteration sharply increases from ~10% to 30-80% depending on assay type (the active scaffolds which are easy to identify are 
quickly retrieved), after which it slowly decreases, as it becomes increasingly difficult to find the remaining highly active scaffolds. Nevertheless, active 
scaffolds are still retrieved at the last iterations.    
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Figure 7. Visualization of stepwise exploration of chemical space for an inhibitory cell-free kinase assay. Expansions for an inhibitory cell-free kinase assay 
are shown in a network graph. All compounds from the starting set (0
th
 iteration) leading to no further expansions have been omitted from the network graph, 
whereas those that led to at least one further expansion are depicted on the large circle on the left part of the figure. All the compounds present in the subnetwork 
in the upper-right corner of the figure represent expansions from one single compound from the starting set (MoABox). In the lower-right corner of the figure, we 
show an example of scaffold hopping, which is commonly caused by expansions based on biological similarity (HTS-FP), enabling the method to explore 
chemical space that is not reachable via expansions based on chemical similarity. In addition, the depiction of activity cliffs
37
 (represented by bold and wide 
edges) allows the identification of scaffold hopping leading to relatively sharp increases in activity.       
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Figure 8. Effect of varying the number of compounds triaged per iteration in terms of median compound 
rank and percentage cumulatively retrieved highly active scaffolds. As the number of compounds triaged 
increases, the median ranks consistently increase for iterations 1 to 10, whereas scaffold retrieval is higher as well. 
These results are in accordance with our expectations: as the number of triaged compounds is increased (i.e. a less 
 29 
stringent selection criterion is applied for compound triaging), more expansions take place and more compounds are 
screened overall. 
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Tables section 
Table 1. Summary of parameters explored over 9 in silico experiments. Here, experiment 1 was considered as the reference experiment, which was chosen 
on basis of a trade-off between number of compounds screened over 10 iterations (approximately 1% of screen size) and performance. All other experiments 
varied one parameter, therefore allowing an assessment of its influence with respect to the reference experiment. For example, a comparison of experiment 3 with 
experiment 1 shows the effect of doubling (from 100 to 200) the number of compounds triaged per iteration.  
Experiment 
number 
Iteration 
count 
Triaged 
number of 
compounds 
Maximum number 
of expansions 
(structure-based) 
Tanimoto cut-
off (structure-
based) 
Maximum number 
of expansions 
(HTS-FP-based) 
Tanimoto cut-off 
(HTS-FP-based) 
Maximum number of 
compounds triaged 
per parent compound 
1 10 100 50 0.6 50 0.6 5 
2 10 50 50 0.6 50 0.6 5 
3 10 200 50 0.6 50 0.6 5 
4 10 100 100 0.6 50 0.6 5 
5 10 100 50 0.8 50 0.6 5 
6 10 100 50 0.6 100 0.6 5 
7 10 100 50 0.6 50 0.8 5 
8 10 100 50 0.6 50 0.6 2 
9 10 100 50 0.6 50 0.6 10 
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Supporting Information 
Supplementary Table S2. Assay types used for retrospective validation. All 34 assays comprise at least 
1,300,000 compounds.  
Biological events Number of HTS assays 
Antibacterial activity 1 
Binding activity 2 
Cell proliferation 1 
Enzyme activity 14 
Gene expression 1 
Phosphorylation/enzyme activity 3 
Protein cleavage 1 
Protein function 5 
Protein protein binding 1 
Receptor internalization 1 
Repopulation 1 
Unclassified 3 
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Supplementary Figure S1. Overview of physicochemical properties, and chemical and biological diversity of 
the MoABox. The following properties are summarized for the MoABox: H-bond donors, H-bond acceptors, 
molecular weight, cLogP, ring count, topological polar surface area. The bottom two figures show how many 
nearest neighbors can be found in the entire screening collection for how many MoABox compounds. A Tanimoto
30
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cut-off of 0.6 was used to define (structurally or biologically) similar compounds. The MoABox compounds have 
properties favorable for cell-based screening. 
Supplementary Figure S2. Overview of frequency densities of physicochemical properties and pairwise 
similarity of the MoABox. The frequency densities of the following properties are shown for the MoABox: cLogP, 
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H-bond acceptor count, H-bond donor count, heavy atom count, molecular weight and pairwise (structural) 
similarity. The MoABox compounds have properties favorable for cell-based screening. 
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Scaffold Prevalence 
1.  
1.4% 
2.  
0.93% 
3.  
0.50% 
4.  
0.14% 
5.  
0.14% 
Supplementary Figure S3. Examples of commonly retrieved scaffolds for iterations 1–10 for all assay types. 
While the scaffolds are not rank ordered according to their prevalence (for example, many scaffolds with a 
prevalence higher than 0.14% are not shown in the figure), scaffold 1 is the second most commonly retrieved 
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scaffold by the ISA, corresponding to a prevalence of 1.4% in the compounds screened for all assays in iterations 1 
to 10. This indicates that the diversity of the compound sets selected by the ISA is large. 
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Supplementary Figure S4. Cumulatively retrieved highly active scaffolds (%) for all assay types compared to the “best possible performance”. The gray 
area represents the 95% confidence interval for the corresponding assay type based on a linear model. When the “best possible performance” retrieves ~75% of 
highly active scaffolds, the ISA retrieves approximately ~10-25% of highly active scaffolds (depending on assay type).   
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Supplementary Figure S5. Effect of varying the number of compounds triaged per iteration in terms of the fraction of highly active scaffolds retrieved 
(%). As more compounds are triaged, more compound expansions take place and more compounds are screened overall. As a consequence, the fraction of highly 
active scaffolds retrieved for every iteration decreases consistently. 
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Supplementary Figure S6. Illustration of the effect of varying the number of compounds triaged per iteration using networks for an inhibitory cell-free 
kinase assay. As more compounds are triaged, more compound expansions take place and more compounds are screened overall. For example, the compounds 
belonging to the subnetwork in the lower-right corner of the figure can be found by the algorithm by triaging 100 or more compounds per iteration (these 
compounds are not found in case only 50 compounds are triaged per iteration). 
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Supplementary Figure S7. The effect of expansion type on highly active scaffold retrieval. HTS-FP-based expansions accounted for 90% of total highly 
active scaffold retrieval, whereas structure-based expansions only accounted for 50%. This can be explained by the fact that HTS-FP capture the biological 
similarity between compounds and therefore, HTS-FP-based expansions lead to more structurally diverse sets of biologically similar compounds, compared to 
structure-based expansions. 
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Supplementary Figure S8. The effect of using randomly selected starting sets on median ranks and highly 
active scaffold retrieval. Using the MoABox as starting set resulted in better median ranks until the first iteration 
and virtually identical median ranks for iteration two onwards, and slightly higher scaffold retrieval throughout all 
iterations. While minor differences across starting sets can be observed, the key findings presented in this study are 
independent of the precise composition of the starting set.  
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